Brief: Kala Bio Q2 EPS USD -3.16
Kala Bio Inc Expected To Post A Loss Of $4.40 A Share: Earnings Preview
Brief: KALA Bio Files For Shelf Of Up To 3.5 Mln Shares By Selling Stockholders
Brief: Baker Bros Advisors Lp Reports 19.99% Stake In Kala Bio Inc As Of June 26
Kala Bio Inc Reports Results For The Quarter Ended In March: Earnings Summary
Brief: Kala Pharmaceuticals Q1 EPS USD -4.2
Kala Bio Inc Expected To Post A Loss Of $2.89 A Share: Earnings Preview
Kala Bio Inc Reports Results For The Quarter Ended In December: Earnings Summary
Brief: Kala Pharmaceuticals Q4 EPS USD -3.18
Brief: Ophthalmic Company KALA BIO Enters Securities Purchase Agreement With Certain Institutional Investors
Brief: KALA BIO Says Co Targeting Reporting Topline Safety, Efficacy Data From CHASE Phase 2b Clinical Trial By 2024 End
Kala Bio Inc Expected To Post A Loss Of $2.15 A Share: Earnings Preview
Kala Bio Inc Reports Results For The Quarter Ended In June: Earnings Summary
Brief: KALA BIO Reports Second Quarter 2023 Financial Results
Brief: Kala Pharmaceuticals Q2 EPS USD -4.36
Brief: Kala Pharmaceuticals Announces Name Change To Kala Bio
Brief: Kala Pharmaceuticals Reports Q1 2023 Financial Results And Provides Corporate Update
Brief: Combangio, Inc., A Wholly Owned Subsidiary Of Kala Pharmaceuticals, Awarded $15 Million By California Institute For Regenerative Medicine To Support Ongoing Kpi-012 Program For The Treatment Of Pced
U.S. STOCKS ON THE MOVE-SiriusPoint, Nutex Health, Barrick Gold